The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2019 | The value of MRD testing in transplant-eligible patients
MRD testing has proven to be significant in determining treatment endpoint in patients with multiple myeloma. Here, Maria-Victoria Mateos, MD, PhD, of University Hospital of Salamanca, Salamanca, Spain, talks about the value of MRD testing in transplant-eligible patients. Dr Mateos was speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.
